Singh Gurjot, Yoshida Eric M, Rathi Sahaj, Marquez Vladimir, Kim Peter, Erb Siegfried R, Salh Baljinder S
Department of Medicine, University of British Columbia, Vancouver V5Z 1M9, Canada.
Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver V5Z 1M9, Canada.
World J Hepatol. 2020 Sep 27;12(9):558-573. doi: 10.4254/wjh.v12.i9.558.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. If diagnosed early, curative treatment options such as surgical resection, loco-regional therapies, and liver transplantation are available to patients, increasing their chances of survival and improving their quality of life. Unfortunately, most patients are diagnosed with late stage HCC where only palliative treatment is available. Therefore, biomarkers which could detect HCC early with a high degree of sensitivity and specificity, may play a crucial role in the diagnosis and management of the disease. This review will aim to provide an overview of the different biomarkers of HCC comprising those used in the diagnosis of HCC in at risk populations, as well as others with potential for prognosis, risk predisposition and prediction of response to therapeutic intervention.
肝细胞癌（HCC）是全球癌症相关死亡的第三大主要原因。如果能早期诊断，患者可获得手术切除、局部区域治疗和肝移植等根治性治疗选择，从而增加生存机会并改善生活质量。不幸的是，大多数患者被诊断为晚期HCC，此时仅能进行姑息治疗。因此，能够高度灵敏且特异检测HCC的生物标志物，可能在该疾病的诊断和管理中发挥关键作用。本综述旨在概述HCC的不同生物标志物，包括用于高危人群HCC诊断的生物标志物，以及其他具有预后、风险易感性和治疗干预反应预测潜力的生物标志物。
